OncoHost, global leader in host response profiling for improved personalized cancer therapy, announced today that its abstract on the use of advanced bioinformatic analysis and machine learning tools on plasma proteomics in order to predict outcomes of immunotherapy-treated melanoma patients was accepted for the American Society of Clinical Oncology (ASCO) 2020 Virtual Poster Discussion Session. The study is in collaboration with the Technion Institute of Technology, the University of Connecticut and Yale University School of Medicine and Cancer Center.

Read more here.